Eccles Health Sciences Library
 
126 - 150 of 507
Number of results to display per page
TitleDateTypeSetname
126 Eosinophilic Variant of Orbital Granulomatosis with Polyangiitis with Hyperimmunoglobulinemia E: A Case Report2018-03Textehsl_novel_nam
127 Longitudinal Inter-Eye Difference Threshold by Optical Coherence Tomography in Multiple Sclerosis (MS)2022-02Textehsl_novel_nam
128 A Rare Presentation of Rhupus as an Arteritic Anterior Ischemic Optic Neuropathy: A Case Report2020-03Textehsl_novel_nam
129 Genotype-Phenotype Correlations in Autosomal Dominant Optic Atrophy2022-02Textehsl_novel_nam
130 Monocular Visual Field Defect (VFD) Presenting Feature of Neurovascular Disorder2020-03Textehsl_novel_nam
131 Central Serous Retinopathy Along With Optic Neuritis as the Initial Presentation of Multiple Sclerosis2021-02Textehsl_novel_nam
132 Slow eye movement fatigability in Myasthenia Gravis2019-03Textehsl_novel_nam
133 Genotype-Phenotype Correlations in Autosomal Dominant Optic Atrophy2022-02Image/MovingImageehsl_novel_nam
134 Enigmatic Optic Neuritis2020-03Textehsl_novel_nam
135 Gazing into the Crystal Ball: Calciphylaxis Causing Orbital Ischemia and Crystalline Retinopathy2020-03Textehsl_novel_nam
136 Adult with Acquired Oblique Diplopia: Do I Image? Do I Operate? (Video)2020-03Image/MovingImageehsl_novel_nam
137 VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Phase 1/2 Clinical Study in Patients2023-03Image/MovingImageehsl_novel_nam
138 Neurosarcoidosis: An Elusive Diagnosis in a Presentation of Isolated Optic Neuropathy2023-03-14Textehsl_novel_nam
139 Characterization of VRDN-001, a High Affinity and Potent Anti-IGF-1R Inhibitory Antibody in Development for the Treatment of Thyroid Eye Disease2022-02Textehsl_novel_nam
140 VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab2023-03-14Textehsl_novel_nam
141 VRDN-002, a Next-Generation Novel Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Results of a Phase 1 Trial2023-03-14Textehsl_novel_nam
142 Efficacy of Chronic Immunotherapy for Myelin Oligodendrocyte Glycoprotein-IgG Disease2019-03Textehsl_novel_nam
143 What's New in Graves' Orbitopathy?2018-04Image/MovingImageehsl_novel_nam
144 Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results2021-02Textehsl_novel_nam
145 Associations Between Pattern Electroretinogram and Intra-retinal Layer Thicknesses in Patients Multiple Sclerosis2019-04Textehsl_novel_nam
146 Visual Loss Due to High Corneal Astigmatism in Thyroid Eye Disease: Another Dysthyroid Optic Neuropathy Masquerader2004-03-31Textehsl_novel_nam
147 Quantification of Saccadic Fatigability for a Diagnosis of Myasthenia Gravis2023-03-14Textehsl_novel_nam
148 Neuro-Ophthalmic Manifestations of Acute Leukemia2020-03Textehsl_novel_nam
149 Presentation of Giant Cell Arteritis with Normal Inflammatory Markers2020-03Textehsl_novel_nam
150 Teprotumumab Effect on Proptosis, Diplopia and Quality of Life in Active Thyroid Eye Disease (TED) (PDF)2020-03Textehsl_novel_nam
126 - 150 of 507